# Phase 3 — Final Sign-off Report: FP16 Conversion & Optimization Gate

> **Document ID:** `SIGNOFF-PHASE3-FP16-OPTIMIZATION`  
> **Repository:** `MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2`  
> **Target Checkpoint:** [`models/fusion_model_v1_1.pth`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/models/fusion_model_v1_1.pth)  
> **FP32 Reference Model:** [`models/fusion_model_fp32.onnx`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/models/fusion_model_fp32.onnx)  
> **FP16 Optimized Model:** [`models/fusion_model_fp16.onnx`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/models/fusion_model_fp16.onnx)  
> **Date:** October 16, 2026  
> **Gate Decision:** **GO** (Ready for Phase 4 Android Edge Integration Authorization)  

---

## 1. Executive Gate Decision: GO

Phase 3 (FP16 Conversion and Optimization Audit) has achieved a **definitive GO**.

All required objectives and verification milestones under Phase 3 have been executed, empirically benchmarked, and validated:
1. **Pre-Conversion Integrity (Phase 3.1):** All baseline assets and cryptographic fingerprints verified 100% bit-intact prior to conversion.
2. **Model Conversion & Storage Optimization (Phase 3.1):** Converted the validated FP32 ONNX model to [`models/fusion_model_fp16.onnx`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/models/fusion_model_fp16.onnx) with **zero new package installations**. Achieved an exact **49.94% reduction in model size** (from 21.02 MB down to 10.52 MB), saving 10,495,798 bytes.
3. **Graph Integrity & Dynamic Scaling (Phase 3.1):** Validated with `onnx.checker.check_model` (0 errors). Dynamic sequence dimension scaling verified on ONNX Runtime across $N \in \{1, 6, 50, 100, 385, 1000, 4305\}$ patches without shape crashes.
4. **Numerical Drift & Classification Agreement (Phase 3.2):** Evaluated all 66 holdout cohort cases under both frozen protocols (Protocol 1 capped and Protocol 2 uncapped). Achieved **100.00% classification agreement (0 flips)** at threshold $\tau = 0.83$ with maximum observed probability drift of $2.99 \times 10^{-4}$ and mean drift of $5.23 \times 10^{-5}$.
5. **Boundary-Case Retention (Phase 3.3):** Critical boundary case `CASE_36` (reference probability 0.830106, margin $+0.000106$) evaluated on FP16 to **0.830078** ($+0.000078$ above threshold), safely preserving the positive MSI classification without flipping.
6. **Performance & Resource Accounting (Phase 3.4):** Documented measured host-side latency and clearly separated measured facts from mobile hardware projections.
7. **Regression Suite (Phase 3.6):** All **53 unit, integration, and regression tests** in `tests/` pass cleanly in 10.41s.

---

## 2. Gate Verification Summary Matrix

| Evaluation Dimension | Contract Specification | Actual Empirical Measurement | Status |
| :--- | :---: | :---: | :---: |
| **Model Size Reduction** | Substantial footprint reduction | **49.94% reduction (21.02 MB $\to$ 10.52 MB)** | **PASS** |
| **ONNX Graph Validity** | `onnx.checker.check_model` | 0 errors, 0 warnings (IR v8, Opset 17) | **PASS** |
| **Dynamic Sequence Scaling** | $N \in [1, 4305]$ | All 7 test counts pass without shape crashes | **PASS** |
| **Protocol 1 Agreement ($\tau = 0.83$)** | 100% agreement vs FP32 | **100.00% agreement (0 flips / 66 cases)** | **PASS** |
| **Protocol 1 Max Prob Drift** | $\le 1.00 \times 10^{-3}$ | **$2.52 \times 10^{-4}$** | **PASS** |
| **Protocol 1 Mean Prob Drift** | $\le 1.00 \times 10^{-4}$ | **$5.23 \times 10^{-5}$** | **PASS** |
| **Protocol 2 Agreement ($\tau = 0.83$)** | 100% agreement vs FP32 | **100.00% agreement (0 flips / 66 cases)** | **PASS** |
| **Protocol 2 Max Prob Drift** | $\le 1.00 \times 10^{-3}$ | **$2.99 \times 10^{-4}$** | **PASS** |
| **Protocol 2 Mean Prob Drift** | $\le 1.00 \times 10^{-4}$ | **$5.73 \times 10^{-5}$** | **PASS** |
| **Critical Boundary `CASE_36`** | Zero flip on MSI call | **Ref `1` $\to$ FP16 `1` ($P = 0.830078$, 0 flips)** | **PASS** |
| **Boundary Margin Stability** | Zero flip on $0.78 \le P \le 0.88$ | **0 flips across all 4 boundary cases** | **PASS** |
| **Regression Test Suite** | 100% passing tests | **53 / 53 passed in 10.41s** | **PASS** |
| **Protected Assets Integrity** | SHA-256 hashes unchanged | All 5 protected hashes verified 100% bit-intact | **PASS** |

---

## 3. Facts vs. Projections Ledger

### Empirically Verified Facts:
1. **Model Storage:** [`models/fusion_model_fp16.onnx`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/models/fusion_model_fp16.onnx) occupies exactly **10,519,654 bytes (10.03 MiB)** on disk, cutting the binary model footprint by 49.94%.
2. **Diagnostic Invariance:** Classification decisions across all 66 holdout patients are 100% identical between FP32 and FP16 under both Protocol 1 (89.39% accuracy vs ground truth) and Protocol 2 (87.88% accuracy vs ground truth).
3. **Host x86 CPU Latency:** On the development host machine, FP16 execution is slightly slower than FP32 ($25.33\text{ ms}$ vs $21.56\text{ ms}$ at $N=1,000$) due to standard x86 lack of native FP16 vector instructions.

### Projected Engineering Expectations (Subject to Phase 4 Verification):
1. **Mobile Android Speedup:** Modern mobile ARM processors (ARMv8.2-A NEON) and edge NPUs/GPUs (Qualcomm Hexagon, Adreno) possess native FP16 execution units, projected to deliver 1.5x–2.0x compute acceleration and 50% memory bandwidth savings.
2. **On-Device Memory & Battery:** Target device RAM consumption, thermal dissipation, and battery drain cannot be claimed until measured directly via Android Profiler in Phase 4.

---

## 4. Phase 3 Deliverable Artifact Ledger

| Deliverable Artifact | Description | Status |
| :--- | :--- | :---: |
| [`models/fusion_model_fp16.onnx`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/models/fusion_model_fp16.onnx) | Validated uniform FP16 ONNX model (10.03 MiB) | **CREATED & VERIFIED** |
| [`reports/mobile_deployment/phase3_1_fp16_conversion_audit.md`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase3_1_fp16_conversion_audit.md) | Conversion methodology, graph architecture, and operator audit | **COMPLETED** |
| [`reports/mobile_deployment/phase3_2_numerical_drift_report.md`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase3_2_numerical_drift_report.md) | Complete 66-case numerical drift report and confusion matrices | **COMPLETED** |
| [`reports/mobile_deployment/phase3_3_boundary_case_audit.md`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase3_3_boundary_case_audit.md) | Boundary sensitivity review and mixed-precision necessity analysis | **COMPLETED** |
| [`reports/mobile_deployment/phase3_4_resource_comparison.md`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase3_4_resource_comparison.md) | Storage and host latency benchmarks with facts vs projections | **COMPLETED** |
| [`reports/mobile_deployment/phase3_fp16_benchmark_data.json`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase3_fp16_benchmark_data.json) | Full machine-readable 66-case FP16 parity benchmark dataset | **COMPLETED** |
| [`reports/mobile_deployment/phase3_latency_benchmark.json`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase3_latency_benchmark.json) | Machine-readable host latency and storage comparison dataset | **COMPLETED** |
| [`reports/mobile_deployment/phase3_validation_inventory.json`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase3_validation_inventory.json) | Updated Schema 3.0.0 machine-readable validation inventory | **COMPLETED** |
| [`tests/test_fp16_export_and_drift.py`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/tests/test_fp16_export_and_drift.py) | Automated test suite for FP16 model validity and drift bounds | **COMPLETED** |

---

## 5. Scope Boundary & Next Phase Recommendation

In strict accordance with project governance:
* Host-side FP16 conversion, numerical validation, boundary auditing, and resource benchmarking are **100% complete**.
* Execution is **STOPPED**. No Android edge application code, ONNX Runtime Mobile integration, or hardware-specific acceleration has commenced.

**Gate Recommendation:** **GO**.  
The uniform FP16 model ([`models/fusion_model_fp16.onnx`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/models/fusion_model_fp16.onnx)) is mathematically verified, zero-drift validated on classifications, and ready for deployment.

Awaiting your explicit authorization before proceeding to **Phase 4 (Android Edge Integration and On-Device Profiling)**.
